Prevention and treatment of cardiomyopathy and heart failure in patients receiving Cancer Chemotherapy

Current Treatment Options in Cardiovascular Medicine

Volumn 10, Issue 6, 2008, Pages 486-495

  Cardinale, Daniela ^a   Colombo, Alessandro ^a   Cipolla, Carlo Maria ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARNITINE; CARVEDILOL; DEFEROXAMINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EDETIC ACID; ENALAPRIL; EPIRUBICIN; IDARUBICIN; LIPOSOME; LISINOPRIL; MITOXANTRONE; PROBUCOL; RAZOXANE; RENIN; TAXANE DERIVATIVE; TRASTUZUMAB; TROPONIN I; UBIDECARENONE; UNINDEXED DRUG;

ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MONOTHERAPY; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 58649119031     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-008-0041-x     Document Type: Review

References (50)

1. Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf 2000, 22:263-302.
2. Yeh ETH, Tong AT, Lenihan DJ, et al.: Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis and management. Circulation 2004, 109:3122-3131.
3. Barry E, Alvarez JA, Scully RE, et al.: Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8:1039-1058.
4. Jones RL, Ewer MS: Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006, 6:1229-1249.
5. Suter TM, Ewer MS: Trastuzumab-associated cardiotoxicity. In Cancer and the Heart. Edited by Ewer MS, Yeh ETH. Hamilton, ON: BC Decker Inc; 2006:64-67.
6. Youssef G, Links M: The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005, 5:233-243.
7. Wouters KA, Kremer LC, Miller TL, et al.: Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol 2005, 131:561-578.
8. Silber JH, Cnaan A, Clark BJ, et al.: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004, 22:820-828.
9. Healey Bird BRJ, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14:14-24.
10. Libby P, Bonow RO, Mann DL, Zipes DP: The cancer patient and cardiovascular disease. In Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: Saunders Elsevier; 2008:2105-2117.
11. Felker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
12. Adams KF, Dunlap SH, Sueta CA, et al.: Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996, 28:1781-1788.
13. Cheitlin MD, Armstrong WF, Aurigemma GP, et al.: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003, 108:1146-1162.
14. Steinherz LJ, Graham T, Hurwitz R, et al.: Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992, 89:942-949.
15. Meinardi MT, Van der Graaf WTA, Van Veldhuisen DJ, et al.: Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999, 25:237-247.
16. Nielsen D, Jensen JB, Dombernowsky P, et al.: Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990, 8:1806-1810.
17. Sabel MS, Levine EG, Hurd T, et al.: Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Am J Clin Oncol 2001, 24:425-428.
18. Jensen BV, Skovsgaard T, Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699-709.
19. Bristow MR, Mason JW, Billingham ME, et al.: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978, 88:168-175.
20. Telli ML, Hunt SA, Carlson RW, et al.: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525-3533.
21. Ewer MS, Henderson C, Martin FJ: Reduction in doxorubicin cardiotoxicity by the use of liposomal formulations of doxorubicin. In Cancer and the Heart. Edited by Ewer MS, Yeh ETH. Hamilton, ON: BC Decker Inc; 2006:64-67.
22. Spallarossa P, Garibaldi S, Altieri P, et al.: Carvedilol prevents doxorubicin-induced free radicals release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004, 37:837-846.
23. Kalay N, Basar E, Ozdogru I, et al.: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258-2262.
24. Panteghini M: Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004, 25:1187-1196.
25. Jensen JK, Atar D, Mickley H: Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol 2007, 15:867-870.
26. Adamcova M, Sterba M, Simunek T, et al.: Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005, 4:457-472.
27. Sparano JA, Brown DL, Wolff AC: Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002, 25:301-311.
28. Cardinale D, Sandri MT, Martinoni A, et al.: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517-522.
29. Cardinale D, Sandri MT, Martinoni A, et al.: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13:710-715.
30. Cardinale D, Sandri MT, Colombo A, et al.: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
31. Lopez-Sendon J, Swedberg K, McMurray J, et al.: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004, 25:1454-1470.
32. Jensen BV, Nielsen SL, Skovsgaard T: Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996, 347:297-299.
33. Okumura K, Jin D, Takai S, Miyazaki M: Beneficial effects of angiotensin-converting enzyme inhibition in adriamycininduced cardiomyopathy in hamsters. Jpn J Pharmacol 2002, 88:183-188.
34. Tokudome T, Mizushige K, Noma T, et al.: Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000, 36:361-368.
35. Vaynblat M, Shah HR, Bhaskaran D, et al.: Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002, 4:583-586.
36. Sacco G, Bigioni M, Evangelista S, et al.: Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001, 414:71-78.
37. Abd El-Aziz MA, Othman AI, Amer M, et al.: Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001, 21:469-473.
38. Maeda A, Honda M, Kuramochi T, et al.: An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol 1997, 24:720-726.
39. Cardinale D, Colombo A, Sandri MT, et al.: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
40. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
41. Cohen M, Kronzon I, Lebowitz A: Reversible doxorubic-ininduced congestive heart failure. Arch Intern Med 1982, 142:1570-1571.
42. Haq MM, Legha SS, Choksi J, et al.: Doxorubicin-induced congestive heart failure in adults. Cancer 1985, 56:1361-1365.
43. Saini J, Rich MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987, 106:814-816.
44. Tallaj JA, Franco V, Rayburn BK, et al.: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005, 24:2196-2201.
45. Noori A, Lindenfeld J, Wolfel E, et al.: Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 2000, 6:115-119.
46. Mukai Y, Yoshida T, Nakaike R, et al.: Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med 2004, 43:1087-1088.
47. Fazio S, Calmieri EA, Ferravate B, et al.: Doxorubic-ininduced cardiomyopathy treated with carvedilol. Clin Cardiol 1998, 21:777-779.
48. Tabet JY, Meurin P, Ben Driss A, et al.: Beta-blockade intolerance in antracycline-induced cardiomyopathy. Int J Cardiol 2006, 106:132-134.
49. Lenihan DJ: Diagnosis and management of heart failure in the cancer patient. In Cancer and the Heart. Edited by Ewer MS, Yeh ETH. Hamilton, ON: BC Decker Inc; 2006:64-67.
50. Ewer MS, Vooletich MT, Durand JB, et al.: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.